DURECT Corp (NASDAQ:DRRX)
The Company is a pharmaceutical Company developing therapies for the treatment of chronic diseases and conditions with its proprietary drug formulations and delivery platform technologies.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
Options Predictor Rank #48 on 9/11/11. P/C Ratio 0.186 and Call Sizzle 3.817.
Recs
Guessing about an overreaction. More information from Pfizer should help.
Recs
26,48,33
78,55,70
Recs
A small company that develops proprietary drug delivery technologies for their drug development partners. Remember Alza? These guys are a mini-Alza (and they have several ex-Alza guys on the team.) The upside won't be as strong as owning the drug company directly, but this should be a nice portfolio of royalties from several different drug products. I've traded this between this level and $7 a couple times over the years.
Recs
Durect has rebounded well. Hopefully will flourish after earnings call in May. Prices are down right now because of fears in the call. Should exceed $3.00 and beyond.
Recs
Awesome ability to take old drugs and make them more safe. Doctors already know the older drugs, so making them even safer makes sales easier and helps minimize potential drug interactions.
Recs
DRRX is going to be a winner in the short and long term. I have been following this stock for the last year or so and feel that it is at a point where it's pipeline is ripe for one of it's partners, namely KING, to come and make a buyout. I don't see it reaching double digits but I do see it as an easy $8.00 buy out candidate over the next year. I already own a fair amount of shares and continue to buy in the dips. However, if it were not bought out I would expect to see it in the double digits by this time next year. I just don't think it will get that far without someone making an offer...
Recs
COMPETENT RESEARCHERS
Recs
REMOXY gets approved
Recs
Don't miss out on this potential Windfall!!! Give it a bit of time to make some great gains!!!
Recs
have a nice mature pipeline and cheap right now
Recs
Pipeline is "loaded". Partnering with some of the best in the field (ENDP).
Recs
Back to it's 52 week high of 6.4 on the news. Fell short today, but it will still have legs.
Recs
Durect has several products in phase II trials that will really be excellent for the treament of post operative pain. Striker, a company that would compete with Durect just purchased something like 18,000,000$ worth of shares of durect. They must think that the new delivery system that durect is making is going to do well. Also, check out the other products that they are developing. They are really great products.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 14 of 14